
    
      A double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses
      (Dose 1 and Dose 2) of QAW039 compared with placebo over a 52-week treatment period in in
      each of the groups (patients with severe asthma and high eosinophil counts and all patients
      with severe asthma). Efficacy will be measured by the rate of asthma exacerbations. In
      addition, asthma quality of life score, asthma control score and lung function will be
      assessed. Safety will be assessed by adverse event monitoring.
    
  